Evotec AG (EVTG.F): New Hormone to Treat Diabetes Published in "Cell"
4/26/2013 11:06:09 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAMBURG, Germany, April 26, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced an auspicious step in research from Harvard University. The findings are published in a scientific article by Prof. Doug Melton, University professor at Harvard University and Howard Hughes Medical Institute (HHMI) investigator and his post doc Peng Yi in the journal Cell. Doug Melton is the academic key collaborator of CureBeta, a strategic alliance between Harvard University, Evotec and Janssen Pharmaceuticals in the field of beta cell regeneration.
Help employers find you! Check out all the jobs and post your resume.
comments powered by